Synthesis And Anti-Inflammatory Activity Of Novel Steroidal Chalcones With 38-Pregnenolone Ester Derivatives In Raw 264.7 Cells In Vitro

To identify new potential anti-inflammatory agents, we herein report the synthesis of novel steroidal chalcones with 38-pregnenolone esters of cinnamic acid derivatives using pregnenolone as the starting material. The structures of the newly synthesised compounds were confirmed by 1H NMR, 13C NMR, HRMS and infrared imaging. All the derivatives were examined to determine their in vitro anti-inflammatory profiles against LPSinduced inflammation in RAW 264.7 cells; the derivates were evaluated by the quantification of the proinflammatory mediator nitric oxide (NO) in the cell culture supernatant based on the Griess reaction, which measures nitrite levels, followed by an in vitro cytotoxicity study. Among these novel derivatives, compound 11e [38-3-phenyl acrylate-pregn-5-en-178-yl-3 ' -(p-fluoro)-phenylprop-2 '-en-1 '-one] was identified as the most potent anti-inflammatory agent, which showed significant anti-inflammatory activity by inhibiting the LPSinduced pro-inflammatory mediator NO in a dose-dependent manner without any cytotoxicity. Moreover, compound 11e markedly inhibited the expression of pro-inflammatory cytokines, including inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-alpha), and cyclooxygenase-2 (COX-2), in LPS-induced RAW 264.7 cells. Further studies confirmed that compound 11e significantly suppressed the transcriptional activity of NF-kappa B in activated RAW 264.7 cells. Molecular docking study revealed the strong binding affinity of compound 11e to the active site of the pro-inflammatory proteins, which confirmed that compound 11e acted as an anti-inflammatory mediator. These results indicated that steroidal chalcones with 38pregnenolone esters of cinnamic acid derivatives might be considered for further research in the design of antiinflammatory drugs, and compound 11e might be a promising therapeutic anti-inflammatory drug candidate.